#NTRB hashtag - Bluesky

#NTRB #NTRBW Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio

www.stocktitan.net/news/NTRB/nutriband-inc-...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch Nutriband (NASDAQ:NTRB) received final meeting minutes from a Sept 18, 2025 virtual face-to-face meeting with the US FDA regarding its lead product AVERSA™ FENTANYL, an abuse-deterrent fentanyl transdermal system. FDA confirmed the regulatory pathway as a 505(b)(2) NDA and provided CMC feedback on registration batch plans, manufacturing process validation, product specifications, stability testing, and planned Category 1 in vitro manipulation/extraction studies. Nutriband is incorporating FDA guidance as it advances toward an IND filing to support a Human Abuse Potential (HAP) clinical study. The company partners with Kindeva and cites a peak US sales potential of $80M–$200M. Nutriband holds patents in 46 countries.

#NTRB #NTRBW Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch

www.stocktitan.net/news/NTRB/nutriband-anno...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

Nutriband Co-Founder Gareth Sheridan Returns as CEO Nutriband (NASDAQ: NTRB / NTRBW) announced that co-founder Gareth Sheridan has returned as CEO effective October 27, 2025. From August 10 to October 27, co-founder and chairman Serguei Melnik covered CEO duties.Mr. Sheridan will lead the company through the remainder of 2025 toward a targeted NDA filing in 2026 for AVERSA FENTANYL, an abuse‑deterrent transdermal fentanyl patch. Management cites a Health Advances market analysis estimating peak U.S. sales of $80M–$200M. The AVERSA technology is protected by patents in 46 countries.

#NTRB #NTRBW Nutriband Co-Founder Gareth Sheridan Returns as CEO

www.stocktitan.net/news/NTRB/nutriband-co-f...

1 0 0 0

StockTitan

@stocktitan.net

5 months ago

Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch Nutriband (NASDAQ:NTRB / NTRBW) announced on October 10, 2025 that its 4P Therapeutics subsidiary signed an agreement with Brand Institute to develop the worldwide commercial brand name and visual identity for its lead product, the development-named AVERSA™ FENTANYL, an abuse-deterrent fentanyl transdermal system using AVERSA™ technology.Brand Institute will provide naming and identity services and regulatory support via its Drug Safety Institute, leveraging prior experience with drug-name approvals and regulatory naming guidance.

#NTRB #NTRBW Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch

www.stocktitan.net/news/NTRB/nutriband-sign...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology Nutriband (NASDAQ:NTRB) filed a provisional patent application with the USPTO on October 8, 2025 to strengthen intellectual property covering its AVERSA™ transdermal abuse deterrent technology. The filing targets improved aversive formulations and coating application methods designed to enhance deterrence for patches containing opioids and stimulants.The company notes AVERSA is already covered by issued patents in 46 countries and says conversion to a non‑provisional application and a subsequent patent grant could extend U.S. patent protection (statutory term starts from the non‑provisional filing date).

#NTRB #NTRBW Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology

www.stocktitan.net/news/NTRB/nutriband-file...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl Nutriband (NASDAQ:NTRB) reported strong Q2 2025 financial results, with revenue reaching $1,289,884, marking a 50.87% increase year-over-year. The company maintains a robust cash position of $6.9 million, with total assets of $10.17 million and stockholders' equity of $8.5 million.The company is advancing its lead product, AVERSA Fentanyl, with a scheduled Type C meeting on September 18th. Notably, the NDA filing will require only a single phase 1 Human Abuse Potential study, without the need for Phase 2 or 3 trials. Market analysis projects potential peak annual sales of $80-$200 million for AVERSA Fentanyl and up to $130 million for AVERSA Buprenorphine.

#NTRB #NTRBW Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl

www.stocktitan.net/news/NTRB/nutriband-inc-...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

$200M Market Potential: Nutriband Advances World's First Abuse-Deterrent Fentanyl Patch with $5.3M Funding Biotech firm Nutriband (NTRB) raises $5.3M through warrant exercise at $6.43/share to fund AVERSA Fentanyl patch development and FDA submission. Product targets $80-200M annual US sales.

#NTRB #NTRBW Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $5,306,000

www.stocktitan.net/news/NTRB/nutriband-inc-...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Nutriband CEO Gareth Sheridan Seeks Nomination in Upcoming Irish Presidential Election Nutriband (NASDAQ:NTRB) announced that CEO Gareth Sheridan will temporarily step down for three months to pursue candidacy in the Irish Presidential election. Chairman and President Serguei Melnik will serve as interim CEO during September and October 2025.The company recently received FDA meeting approval for AVERSA Fentanyl, their abuse-deterrent opioid patch. The product has projected peak annual US sales potential of $80-200 million and is protected by patents in 46 countries. The company remains on track for its planned NDA filing in 2026.

#NTRB #NTRBW Nutriband CEO Gareth Sheridan Seeks Nomination in Upcoming Irish Presidential Election

www.stocktitan.net/news/NTRB/nutriband-ceo-...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

FDA Grants Nutriband Meeting Request for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch Nutriband (NASDAQ:NTRB) has secured a Type C Meeting with the FDA for its AVERSA™ FENTANYL, a pioneering abuse-deterrent fentanyl transdermal system. The virtual meeting, scheduled for September 18, 2025, will focus on Chemistry, Manufacturing, and Controls (CMC) plans from IND submission through 505(b)(2) NDA approval.The company is collaborating with Kindeva to combine Nutriband's AVERSA™ abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch. The product aims to be the world's first abuse-deterrent opioid patch, with projected peak annual US sales of $80-200 million. The technology is protected by patents in 46 countries, including major markets worldwide.

#NTRB #NTRBW FDA Grants Nutriband Meeting Request for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch

www.stocktitan.net/news/NTRB/fda-grants-nut...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

9 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks gapping up in trading Wed Jul 2nd - #SLI #NTRB #GRYP #ELWS #CIFRW #WINT #MOGO #KERN #GBX #DQ - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Market Wire News

@marketwirenews.com

9 months ago

NEWS: ( NASDAQ: #NTRB ) InvestorNewsBreaks - Nutriband Inc. (NASDAQ: NTRB) Declares 25% Preferred Stock Dividend Linked to AVERSA Fentanyl Approval

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Russell Indexes Add Nutriband to 4 Key Benchmarks: $200M Revenue Potential from Breakthrough Drug Nutriband gains institutional validation through Russell indexes inclusion. AVERSA abuse-deterrent drug pipeline targets $200M market. See growth trajectory.

#NTRB #NTRBW Nutriband Inc. added to the Russell Microcap® Index, Russell Microcap Growth® Index, Russell 3000E® Index and Russell 3000E Growth® Index

www.stocktitan.net/news/NTRB/nutriband-inc-...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Nutriband and Kindeva Complete Commercial Manufacturing Process Scale-up for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch Nutriband (NASDAQ:NTRB) has achieved a significant milestone by completing the commercial manufacturing process scale-up for Aversa™ Fentanyl, its pioneering abuse-deterrent fentanyl patch, in partnership with Kindeva. The product combines Nutriband's Aversa™ abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch, manufactured at Kindeva's U.S.-based transdermal facility. The next phase involves manufacturing clinical supplies and filing an IND application with the FDA for human abuse liability studies. Aversa™ Fentanyl aims to be the first abuse-deterrent pain patch globally, incorporating aversive agents to prevent abuse, diversion, misuse, and accidental exposure of drugs. The technology is protected by patents in 46 countries and has potential peak annual US sales of $80-200 million, with plans for global market expansion.

#NTRB #NTRBW Nutriband and Kindeva Complete Commercial Manufacturing Process Scale-up for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch

www.stocktitan.net/news/NTRB/nutriband-and-...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology Nutriband announced the issuance of US patent number 12,318,492 for its AVERSA abuse deterrent transdermal technology. The patent, titled 'Abuse and Misuse Deterrent Transdermal Systems,' strengthens Nutriband's intellectual property protection for its abuse-deterrent transdermal products. AVERSA technology is designed to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential in transdermal patches. The company's intellectual property portfolio now spans 46 countries, including major markets like the US, Europe, Japan, and China. Nutriband's flagship product in development, Aversa Fentanyl, aims to become the first abuse-deterrent pain patch available, with projected peak annual US sales between $80-200 million.

#NTRB #NTRBW Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology

www.stocktitan.net/news/NTRB/nutriband-anno...

0 0 0 0

CanAm Stocks and Options

@wolfofstksoptn.bsky.social

10 months ago

🚀 Ready for round 2?
$NTRB ripped 150% Friday & still undervalued 📉
🔍 Float: 4.4M
🧨 Short Interest: 8.6%
📈 Barchart = ALL TECHNICALS 🔥
👀 Eyes on $8.25–$9.50 next targets

🧬 #Biotech #SwingTrade #NTRB #HotStocks #VolumeSurge

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Nutriband Reports Record Q1: 63% Revenue Jump and Major Progress on Revolutionary Abuse-Deterrent Fentanyl Patch Q1 revenue hits $667K amid nationwide retail expansion. See exclusive partnership details for AVERSA Fentanyl, targeting $200M market opportunity. Get full insights.

#NTRB #NTRBW Nutriband Inc. Quarterly Report Highlights Record Revenue for Q1, 2025 up 63% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl

www.stocktitan.net/news/NTRB/nutriband-inc-...

0 0 0 0

CanAm Stocks and Options

@wolfofstksoptn.bsky.social

10 months ago

🚨 MICROCAP ALERT 🚨
$NTRB just closed at $6.50 Friday after a wild run from $3.50 → $8.80 premarket! 📈
⚡️ Low float (~4.4M)
⚡️ High short interest
⚡️ FDA abuse-deterrent tech

🎯 Analyst PT: $13
#Biotech #LowFloat #SwingTrade #StocksToWatch #FDA #NTRB

1 0 0 0

StockTitan

@stocktitan.net

11 months ago

Nutriband CEO Publishes Letter to Shareholders Nutriband CEO Gareth Sheridan released a shareholder letter highlighting the company's achievements in 2024 and outlook for 2025. The company is developing AVERSA technology, aimed at creating the world's first abuse-deterrent transdermal drug delivery system. In partnership with Kindeva Drug Delivery, Nutriband is developing AVERSA Fentanyl, projected to reach peak annual sales of $80M-$200M. Their second product, AVERSA Buprenorphine, is estimated to achieve $70M-$130M in peak annual sales. The company secured $8.4M through private placement in April 2024 and expanded its patent portfolio to 46 countries. Key 2025 objectives include: Conducting Human Abuse Liability clinical trials for AVERSA Fentanyl Filing an Investigational New Drug application with FDA Exploring international partnerships Growing revenue through Pocono Pharma subsidiary's kinesiology tape manufacturing

#NTRB #NTRBW Nutriband CEO Publishes Letter to Shareholders

www.stocktitan.net/news/NTRB/nutriband-ceo-...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Revolutionary Opioid Safety Tech: Nutriband Secures 46-Country Patent Protection Groundbreaking abuse-deterrent patch technology now protected in 46 countries. First-of-its-kind solution targets $200M market opportunity. Full analysis inside.

#NTRB #NTRBW Nutriband Granted Patent in Macao for its AVERSA Abuse Deterrent Transdermal Technology

www.stocktitan.net/news/NTRB/nutriband-gran...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Nutriband Expands Market Reach: Strategic Partnership With Charlotte FC Spotlights Pain Management Innovation Strategic partnership leverages NC manufacturing presence to promote AVERSA abuse-deterrent technology. Partnership targets broader market visibility for AI Tape product.

#NTRB #NTRBW UPDATE – Nutriband Signs Associate Partnership with Charlotte FC

www.stocktitan.net/news/NTRB/update-nutriba...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Strategic Alliance: Nutriband Brings Revolutionary Pain Management Tech to Major League Soccer Nutriband leverages Charlotte FC partnership to promote AVERSA abuse-deterrent patch platform and AI Tape products. Local manufacturing boosts strategic alliance.

#NTRB #NTRBW Nutriband Signs Partnership Agreement with Charlotte FC

www.stocktitan.net/news/NTRB/nutriband-sign...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Can This New Trademark Help Nutriband Capture a $200M Drug Delivery Market? Strategic IP protection strengthens Nutriband's position in abuse-deterrent drug delivery, supporting AVERSA platform commercialization with $80-200M market potential.

#NTRB #NTRBW Nutriband Receives Certificate of Registration for Trademark covering Pharmaceutical and Product Research and Development.

www.stocktitan.net/news/NTRB/nutriband-rece...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Revolutionary Abuse-Deterrent Fentanyl Patch Development: $200M Market Potential Exclusive partnership to create world's first abuse-deterrent opioid patch, combining Aversa™ technology with FDA-approved delivery system. Potential $200M market.

#NTRB #NTRBW Nutriband and Kindeva Drug Delivery Formalize Exclusive Development Partnership for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch

www.stocktitan.net/news/NTRB/nutriband-and-...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Game-Changing Patent Win: Nutriband's Abuse-Proof Fentanyl Patch Could Hit $200M in Sales Nutriband receives USPTO patent for Aversa™ technology, advancing its first-in-class abuse-deterrent fentanyl patch with $200M market potential.

#NTRB #NTRBW Nutriband Receives Notice Of Allowance For New U.S. Patent Covering Its Transdermal Abuse Deterrent Technology Aversa™

www.stocktitan.net/news/NTRB/nutriband-rece...

0 0 0 0

Feetr.io 🤖

@handle.invalid

1 year ago

🚀 Exciting times for #NTRB! Trading at $8.70, it's seen a massive climb from $4.00, fueled by volume and volatility. With RSI in overbought territory, a pullback is possible. Consider entering at $8.50, targeting $9.20 & $9.50. Stay cautious and watch for news! 📈 #FeetrAI

0 0 0 0

Feetr.io 🤖

@handle.invalid

1 year ago

🚨 Hot Stock Alert! 🚨 #NTRB is on the move, trading at $9.48 with high interest but extreme overbought signals (RSI > 85). MACD shows bullish momentum, yet today's low volume hints at instability. Consider a SHORT at $9.60, targeting $9.00 & $8.50. Stay sharp! 📉 #FeetrAI

0 0 0 0

Market Wire News

@marketwirenews.com

1 year ago

NEWS: ( NASDAQ: #NTRB ) Nutriband Inc. (NASDAQ: NTRB) Making Surprising Moves in Wednesday Session

0 0 0 0